Mingyan Jiang

Xiangtan Central Hospital

Xiangtan

China

SCHOLARLY PAPERS

1

DOWNLOADS

38

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Rezivertinib Versus Gefitinib as First-Line Therapy for EGFR-Mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-Blinded, Randomized Phase 3 Study

Number of pages: 26 Posted: 13 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Henan University of Science and Technology - Department of Medical Oncology, Zhengzhou University - Department of Oncology, Zhengzhou University - Henan Provincial People's Hospital, People's Hospital of Deyang City, Shanxi Medical University - First Hospital, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Sichuan Cancer Hospital - Department of Medical Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Sichuan University - Department of Respiratory and Critical Care Medicine, Guangxi Medical University, Shandong First Medical University - Department of Oncology, Qingdao University - Yantai Yuhuangding Hospital, Fujian Medical University - Fujian Cancer Hospital, Shantou University - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Army Medical University - Institute of Cancer, Xingtai Medical College - Cancer Center, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Gannan Medical University - First Affiliated Hospital, Central South University - Department of Respiratory Medicine, University of South China, Central South University, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Xinjiang Medical University - Pulmonary Cancer Medicine, Hubei University of Arts and Science - Department of Oncology, Xinjiang Medical University, Qingdao University - Affiliated Hospital, Qingdao University - Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Peking University - Department of Thoracic Medical Oncology, Cangzhou Central Hospital, Xi'an Jiaotong University (XJTU), China Medical University - Liaoning Cancer Hospital & Institute, Xiangtan Central Hospital, Nankai University - Tianjin Chest Hospital, Nanjing Medical University - Department of Oncology, Xiamen University, Huazhong University of Science and Technology - Department of Medical Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Henan University - Department of Oncology, Ningbo No. 2 Hospital, Zhengzhou University - Department of Medical Oncology, Shijiazhuang People’s Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Chifeng Municipal Hospital, Handan Central Hospital - Department of Oncology, Tianjin Medical University - The Second Hospital of Tianjin Medical University, Government of the People's Republic of China - Army Medical University, Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 38 (946,131)

Abstract:

Loading...

rezivertinib, gefitinib, NSCLC, EGFR TKI.